New therapeutic perspectives in CCDC6 deficient lung cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality globally, necessitating novel therapeutic approaches.
• The tumor suppressor gene CCDC6 plays a role in apoptosis and DNA damage response pathways.
• Understanding CCDC6's function is crucial for developing targeted treatments for NSCLC.

Purpose of the Study:

• To investigate the role of CCDC6 expression in NSCLC cell lines and patient tumors.
• To determine the association between CCDC6 levels, DNA repair capacity, and response to chemotherapy.
• To evaluate CCDC6 as a potential predictive biomarker for NSCLC treatment.

Main Methods:

• Characterization of NSCLC cell lines for CCDC6 expression.
• Assessment of DNA damage response and homologous recombination repair in CCDC6-deficient cells.
• Evaluation of drug sensitivity to cisplatinum and olaparib (PARP inhibitor) in NSCLC cells.
• Analysis of CCDC6 expression in NSCLC tumors using tissue microarray (TMA) immunostaining.

Main Results:

• Low CCDC6 protein levels correlated with impaired DNA damage response and reduced Rad51 foci.
• CCDC6 deficiency led to defects in homologous recombination repair.
• CCDC6-low NSCLC cells were resistant to cisplatinum but sensitive to olaparib.
• Combined cisplatinum and olaparib treatment showed synergistic efficacy (combination index <1).
• Approximately 30% of NSCLC tumors exhibited low CCDC6 expression, which was significantly associated with lymph node metastasis and poorer disease-free and overall survival.

Conclusions:

• CCDC6 functions as a critical regulator of DNA repair in NSCLC.
• Low CCDC6 expression is a predictive biomarker for resistance to conventional therapy and sensitivity to PARP inhibitors in NSCLC.
• Targeting CCDC6 status may offer a personalized therapeutic strategy for NSCLC patients.